Treventis Corporation
https://treventis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Treventis Corporation
Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.
Venture Funding Deals: Vedanta Raises More Cash To Advance Microbiome Candidates
Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter.
Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks
Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.
Selected Start-Ups (09/2009)
In Vivo briefly describes these recently founded companies: Acetylon Pharmaceuticals, Avineuro Pharmaceuticals, Nanovis, TargAnox, TheraCell and Treventis.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice